²é¿´ÍêÕû°æ±¾: [-- µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ --]

¿¼²©ÂÛ̳ -> µÚËľüÒ½´óѧ -> µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ [´òÓ¡±¾Ò³] µÇ¼ -> ×¢²á -> »Ø¸´Ö÷Ìâ -> ·¢±íÖ÷Ìâ

qddusj 2007-04-19 16:03

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æרҵ£º ,3FG' q2  
[p&2k&.XYe  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ C9"yu&l  
a qIpO  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) b?%Pa\,!  
WTQd}f  
1. ICAM-1 -JfO} DRI  
73>Hzpv0  
2. interleukin 12(IL-12) !DNk!]|  
-x2&IJ!  
3. tumor infiltrating lymphocyte t[Ywp!y[  
xm bFJUMH  
4. TCR/CD3 complex EK<ly"S.  
?D S|vCae  
5. hematopoietin receptor family hxx`f-#=  
dEG 1[QG  
6. individual idiotype(IdI) T +~ _D  
YKG}4{T  
7. integrin px=r~8M9}  
d2[R{eNX=  
8. colony-stimulatory factor (CSF) Tl `HFZQ1  
{BS`v5*  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© /eNDv(g)M  
GMQKR,6VM  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? gWpG-RL0  
A,#a?O6m  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ {2MS,Ua{  
31=v US  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ%r >Y)@$Vt  
N4[^!}4  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØϵ¡£ `as6IMqJD  
T@x_}a:g  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) ;LE9w^>^V  
4oA9|}<FR  
1. ÊÔÊö¸ÉÈÅËصķÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌص㡣Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËؼì²âµÄ·½·¨ºÍÔ­Àí¡£ `g!NFp9q  
>^ijj`{d  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ä¿Ç°¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) z`KP }-  
pA?2UZ  
3. immunoglobulin superfamily (IgSF) ?QG?F9?  
,R2;oF_  
4. selectin [ %:%C]4  
i*2l4  
5. anti-idiotypic antibody (¦ÁId) r"\g6<RP  
u[~= a 5:4  
6. major histocompatibility complex(MHC) X>kW)c4{b  
?2i\E RG?  
7. immunotolerance z((9vi W  
T f;:C]  
8. biological reponse modifier(BRM) n+%tu"e  
1J @43>u{  
9. immune reponse gene (Ir gene) 7zEpuw  
0FG|s#Ig  
10. reshaped antibody (or reconstituted antibody) h(MS>=  
gi5Ffvs$  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© =]<JkWSk  
(X(c.Jj  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ 5B,HJax  
:Yy8Ie#  
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? F,>-+~L=  
A.@Af+  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ >S=,ype~G  
7UA|G2Zr  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? #7yy7Y5  
|{JJ2c\W  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ kFo&!  
8bP4  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? 9a;8^?Ld%S  
=as\Tp#d  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ Xsit4Ma  
>W7IWhm3  
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺ "Ir.1FN  
g1zX^^nd,V  
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? [*|QA 9  
#Y 'svn1H  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ D|rcSa.M  
kx_PMpc  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: |nTZ/MXbw  
X*Dt<i};v  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: [osm\w49  
P2^((c  
ÃâÒßѧ Yt% E,U~g  
!ii'hwFm$  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© </B5^}  
j*05!j<'  
1. CD8 )TFBb\f>v  
u]%>=N(^2  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) !NfN16  
[6Nw)r(a(  
3. immunoglobulin fold(Ig fold) o I6o$C  
QC\][I>  
4. cadherin (Ca-dependent cell adhesion moleculers) E?+MM0  
&QQ8ut,;  
5. idiotype-anti-idiotypic antibody immune network theory &^W91C?<6  
r$Z_Kwe.|&  
6. HLA class II antigen H!NyM}jsr  
aj:B+}1  
7. complementarity-determining region (CDR) c#6g[TE@  
G$"$k=[  
8. perforin(or pore-forming protein ,PFP) L)LW5%.6  
*Tt*\ O  
9. high affinity IL-2 receptor  `=h`:`  
$"/xi `  
10. artificial active immunization bf3Njma%  
r6Hdp  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© %EooGHGF?  
.#] V5g,  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠV~uH)IMkh7  
i: ZL0nH-  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 a3<.F&c+c  
vNhi5EU  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ KnC;j-j  
{i7Wp$ug  
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԭ¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ ByrK|lVM0  
|nN{XjNfP5  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ y0d a8sd)  
D9;2w7v  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? R N1q/H|  
cVt MCgx  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ G 1 rsd  
#-_';Er\  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ ' {L5 3cH=  
:)UF#  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ S0\;FmLIc  
QQso<.d&  
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ "eq{_4dL  
brA\Fp^  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© hlpi- oW`  
SO #NWa<0|  
1. immunoglobulin gene rearrangement BitP?6KX  
4LRrrW  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) 3[g%T2&[  
p&SxR}h  
3. flow cytometry(FCM) _;G. QwHr  
uXX3I E[  
4. carrier effect +*2]R~"M  
zI5 #'<n  
5. positive selection of T lymphocytes in thymus M]O _L  
@l)HX'z0d  
6. mouse TH1(Th1) and TH2(Th2) subsets w-%V9]J1  
< 9JI@\>  
7. perforin (pore-forming protein ,PFP) "@1e0`n Q  
Yv?nw-HM  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) 9`P<|(  
>h^CC*&'pw  
9. SH-2(src-homology region 2) LUGyc( h  
D# ZzhHHP  
10. Ab2¦Â (internal image) i6L>,^Dg  
!^{0vFWE  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© B?BB  
00Tm]mMQX  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? OAoTsqj6  
\LYB% K}  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? C-i9F%..  
~HWH2g  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ9 7 Oi}   
f{ ;L"*L  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ =Q\z*.5j.  
=L,s6J8_'  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ%gK@ R3p  
> -P UY  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) ;WydXQ}Q^  
yQAW\0`  
ÃâÒßѧרҵ£º v:2*<;  
s(~tL-_ K  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ =ttvC"4?  
K90wX1&  
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? :%_*C09  
<ttrd%VW  
´«È¾²¡Ñ§×¨Òµ£º $<;!F=%8  
nK95v}p}Y  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ Ue:LKK1Gsr  
|p4D!M+$7  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ 4Ss4jUj  
r;>2L'  
Ïû»¯×¨Òµ£º v'0WE  
@u@ N&{b5"  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ l(irNKutgo  
T ^ z  
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? I_?+;<n  
9i6z  p'  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ x9DG87P~+  
B=?m_4\$m  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© N7Kg52|  
!^[i"F: G  
1. Fas(CD95)/FasL 0mt lM(  
Q1Jw7R#?l  
2. common chain of cytokine receptor Gy]ZYo(  
(+(YQ2  
3 . TCR/CD3 complex 4!vovt{  
=&_Y=>rA]0  
4. negaive selection of thymocytes \!51I./Q/  
c"wk _ #  
5. artificial active immune 0: 1[F!]'b  
E;o "^[we  
6. anti-idiotypic hL?"!  
Qhc>,v)  
7. IgSF |8{c|Qz  
! %~P[;.  
8. Integrin 3D}rxI8N  
PHxU6UPqy  
9. chemokine -$2B!#]3  
Jan~R ran  
10. B7/CD28 4[XiD*  *  
ZRy'lW  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© w/oXFs&FK  
_{C =d3  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ WSsX*L  
)c<X.4  
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 NMvNw?]  
UhX)?'J  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ `9`T,uJe  
q; ?Kmk  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ 2:jWO_V@  
E4cPCQyeH  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ 7L4~yazmK  
jU}iQM  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ K} ) w  
GlOSCJZ  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© QFg{.F?3q>  
<-(n48  
1. B7/CD28 >mW*K _~  
s= bP@[Gj  
2. Th1 subset MC~<jJ,  
vUR@P  -  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© TMG|"|  
SH5a&OVZhn  
4. antibody affinity maturation DEQ7u`6  
/4YxB,  
5. AP-1 r!&}4lHYi  
'&!:5R59  
6. single chain variable fragment£¨ScFv£© v 8B4%1NE  
miB+'n"zS  
7. NK cell receptor o#QS: '|  
2rWPqG4e  
8. Zinkernagel-Doherty phenomenon PlRcrT"#w  
D}OhmOu 3  
9. Ig fold |.?X ov]  
fn, YH  
10. CD40/CD40L 6){nu rDBG  
<AN5>:k[pM  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© Hn}m}A  
'B;n &tJ   
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ YM&i  
t[p/65L>8  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ Gx; -1  
nP+jkNn3  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ M~ g{}_ 0Z  
2Ft#S8  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ >9,LN;Ic  
3 p!t_y|SX  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ D77s3AyHK  
TGZr [  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ w"q^8"j!  
" ""pe+Y  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ N=j$~,yG  
H`nd |  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© >"[Nmx0;w  
->'xjD  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© rw#?NI:  
]\F}-I[  
1.Co-stimulators (or co-stimulating molecules) -/R?D1kOq  
9P*p{O{_  
2.NK-kB $9ys! <g  
KeWIC,kq  
3.Immunoglobulin superfamily zYEb#*Kar  
=a6e*f  
4.antigen-presenting cell (APC) 7Mb-v}  
u-=VrHff^*  
5.death domain 3K%_wCZ  
COcS w  
6.CCR and CXCR Hl z$@[$  
OE2r2ad  
7.Lectin (or mitogen) @;Xa&*   
c3N,P<#  
8.Clusters of differentiation, CD) o)M<^b3KO  
Nuaq{cl  
9.B7 family (/C 8\}Ox  
#0c;2 }D  
10.Cytotoxic T lymphocyte, CTL) Tua#~.3}J  
eV\VR !!i  
11.IL-15 and IL-15 receptor (IL-15R) Q1P=A:*]9  
7w.9PNhy  
12.MHC restriction .Ix[&+LsY  
ORhvo,.u  
13.Affinity-chromatography :_pn|  
vA*Q}]Ov  
14.Cyctosprin A, CsA s ?|Hw|j  
c:2LG_mQ  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) "ed A  
okH*2F(-  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© ?D=C8EX  
@k\npFKQm  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 d8&T62Dnd4  
ZC 3;QKw>  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ mJ+mTA5 bW  
{11xjvAD  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 =a(]@8$!1  
w/@ tH  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© gq050Bl)  
uuYeXI;  
ÃâÒßѧרҵ£º 6@I r|o  
d bHxc@H  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ &[_D'jm+S0  
64t:  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ a=M/0N{!  
4c@_u8  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ K1zH\wH  
"-g5$v$de  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) bkiMF$K,K  
6\xfoy|j  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) jz,Gj}3;  
SDko#  
1. ADCC(antibody dependent cell-mediated cytotoxicity) $.3J1DU  
S+GW}?!  
2. »·æß¾úËØ(cyclosporin) 3 V$ \s8  
afd.v$63  
3. KIR(killer cell inhibitory receptor) lA n^)EL  
vCn\_Nu;W&  
4. HLDA(human leucocyte differentiation antigen) dY`P  
[@/s! i @  
5. Interleukin 18(IL-18) {~ 1 ~V  
&<t`EI];)4  
6. ÕûºÏËØ(integrin) lfqsoIn;  
p%IVWeZnx  
7. Fas/FasL yZ,S$tSR  
ksF4m_E>YB  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) Vn?|\3KY  
.cB>ab&  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) scZ&}Ni  
fK+[r1^  
10. Th1/Th2 CmdPa!4)  
CIA KXYM  
11. »ùÒòÒßÃç(DNAÒßÃç) 1aoKf F(  
v-}B T+  
12. chemokines and chemokine receptor $LOf2kn  
/`g~lww2O  
13. ÃâÒßÄÍÊÜ =Q4Wr0y><]  
CQ'4 ".7  
14. ¹²´Ì¼¤·Ö×Ó 0xUn#&A~  
!}=#h8fv  
15. ËÀÍö½á¹¹Óò(death domain) T 2Gscey  
(} Y|^uM,  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) U[NQ"  
;ApldoMi  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? V@\A<q%jTs  
O[ z-K K<  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ4\m#:fj %  
mw~$;64;a  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î XRXQ 7\n  
[k60=$y  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ OD).kP}s^  
b;"Z`/h  
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå Sb?HRoe_  
AP0z~e  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ )u.%ycfeV  
W.?EjEx  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) BP8jReX^  
OVEQ^\Q5D  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ 5N$O  
sH :_sOV*  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ yX CJ?  
"2hs=^&8  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£


²é¿´ÍêÕû°æ±¾: [-- µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ --] [-- top --]


Powered by freekaobo v7.5 SP3 Code ©2003-2010 PHPWind
Gzip enabled

You can contact us